Sihuan Pharmaceutical invests in Swiss medical aesthetics firm Suisselle

Reuters
10/13
Sihuan Pharmaceutical invests in Swiss medical aesthetics firm Suisselle

Sihuan Pharmaceutical Holdings Group Ltd. has announced that it made an equity investment in the Swiss medical aesthetic company Suisselle SA in September 2025. This move follows their previous partnership, in which Sihuan Pharmaceutical obtained exclusive distribution rights for Suisselle's CELLBOOSTER® skin booster in China in 2022. The new investment aims to strengthen the strategic cooperation between the two companies and accelerate Sihuan's global expansion in the medical aesthetic market. According to the company, Suisselle and its owners are independent third parties, and the investment does not constitute a connected or discloseable transaction under Hong Kong's Listing Rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10